{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:22:31Z","timestamp":1792891351193,"version":"4.5.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00743","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T09:14:20Z","timestamp":1595582060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":78,"title":["Management of Juvenile Myasthenia Gravis"],"prefix":"10.3389","volume":"11","author":[{"given":"Karen","family":"O'Connell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sithara","family":"Ramdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/archdischild-2013-304788","article-title":"How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia","volume":"99","author":"Parr","year":"2014","journal-title":"Arch Dis Child."},{"key":"B2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ejpn.2016.09.001","article-title":"Juvenile myasthenia gravis in Norway: a nationwide epidemiological study","volume":"21","author":"Popperud","year":"2017","journal-title":"Eur J Paediatr Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1468-1331.2012.03850.x","article-title":"Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996\u20132009","volume":"20","author":"Pedersen","year":"2013","journal-title":"Eur J Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ajo.2019.01.004","article-title":"Incidence and ocular features of pediatric myasthenias","volume":"200","author":"Mansukhani","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/mus.24348","article-title":"Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa","volume":"51","author":"Mombaur","year":"2015","journal-title":"Muscle Nerve."},{"key":"B6","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10072-012-1157-z","article-title":"Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years","volume":"34","author":"Huang","year":"2013","journal-title":"Neurol Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000311012","article-title":"Nationwide population-based epidemiological study of myasthenia gravis in taiwan","volume":"35","author":"Lai","year":"2010","journal-title":"Neuroepidemiology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.nmd.2019.11.008","article-title":"Paediatric myasthenia gravis: prognostic factors for drug free remission","volume":"30","author":"Vecchio","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B10","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/nyas.13513","article-title":"The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure","volume":"1412","author":"Ghazanfari","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1469-8749.2007.00629.x","article-title":"Childhood myasthenia: clinical subtypes and practical management","volume":"49","author":"Parr","year":"2007","journal-title":"Dev Med Child Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pediatrneurol.2018.06.007","article-title":"Juvenile ocular myasthenia gravis: presentation and outcome of a large cohort","volume":"87","author":"Vanikieti","year":"2018","journal-title":"Pediatr Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ajo.2010.05.002","article-title":"Visual and systemic outcomes in pediatric ocular myasthenia gravis","volume":"150","author":"Pineles","year":"2010","journal-title":"Am J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.nmd.2013.07.010","article-title":"Muscle specific kinase autoimmune myasthenia gravis in children: a case series","volume":"23","author":"Skjei","year":"2013","journal-title":"Neuromuscul Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ejpn.2017.04.003","article-title":"Juvenile myasthenia gravis in Norway: clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort","volume":"21","author":"Popperud","year":"2017","journal-title":"Eur J Paediatr Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00415-015-7638-2","article-title":"Long-term outcome of 424 childhood-onset myasthenia gravis patients","volume":"262","author":"Gui","year":"2015","journal-title":"J Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0883073816666206","article-title":"Juvenile myasthenia gravis in Korea: subgroup analysis according to sex and onset age","volume":"31","author":"Lee","year":"2016","journal-title":"J Child Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7196\/SAMJ.5390","article-title":"The characteristics of juvenile myasthenia gravis among South Africans","volume":"102","author":"Heckmann","year":"2012","journal-title":"S Afr Med J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ncl.2018.01.005","article-title":"An update: myasthenia gravis and pregnancy","volume":"36","author":"Hamel","year":"2018","journal-title":"Neurol Clin."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1212\/NXI.0000000000000057","article-title":"Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","article-title":"Clinical characteristics of juvenile myasthenia gravis in southern China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.nmd.2005.01.010","article-title":"Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years","volume":"15","author":"Anlar","year":"2005","journal-title":"Neuromuscul Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","article-title":"Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases","volume":"270","author":"Rodriguez Cruz","year":"2015","journal-title":"Exp Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pediatrneurol.2019.01.016","article-title":"Cell-based versus enzyme-linked immunosorbent assay for the detection of acetylcholine receptor antibodies in Chinese juvenile myasthenia gravis","volume":"98","author":"Yan","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG.","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells."},{"key":"B33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/mus.25685","article-title":"Use of stimulated electromyography in the analysis of the neuromuscular junction in children","volume":"56","author":"Pitt","year":"2017","journal-title":"Muscle Nerve"},{"key":"B34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.clinph.2016.11.020","article-title":"Assessing neuromuscular junction stability from stimulated EMG in children","volume":"128","author":"Pitt","year":"2017","journal-title":"Clin Neurophysiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.nmd.2020.02.001","article-title":"242nd ENMC international diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019","volume":"30","author":"Munot","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ana.25267","article-title":"Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis","volume":"84","author":"He","year":"2018","journal-title":"Ann Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"CD006986","DOI":"10.1002\/14651858.CD006986.pub3","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","volume":"13","author":"Mehndiratta","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"404101","DOI":"10.4061\/2011\/404101","article-title":"Juvenile myasthenia gravis: a paediatric perspective","volume":"2011","author":"Finnis","year":"2011","journal-title":"Autoimmune Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/mus.21195","article-title":"Juvenile myasthenia gravis","volume":"39","author":"Chiang","year":"2009","journal-title":"Muscle Nerve."},{"key":"B40","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mus.26172","article-title":"Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies","volume":"58","author":"Europa","year":"2018","journal-title":"Muscle Nerve."},{"key":"B41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mus.25965","article-title":"Clinical features and evolution of juvenile myasthenia gravis in a French cohort","volume":"57","author":"Barraud","year":"2018","journal-title":"Muscle Nerve."},{"key":"B43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0404.2006.00646.x","article-title":"Myasthenia gravis in children: a longitudinal study","volume":"114","author":"Ashraf","year":"2006","journal-title":"Acta Neurol Scand."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.therap.2017.06.006","article-title":"Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study","volume":"73","author":"Alami","year":"2018","journal-title":"Therapie."},{"key":"B46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve."},{"key":"B48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1055\/s-0035-1556743","article-title":"Update on the teratogenicity of maternal mycophenolate mofetil","volume":"4","author":"Coscia","year":"2015","journal-title":"J Pediatr Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Ther Adv Neurol Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","article-title":"Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone","volume":"77","author":"Liu","year":"2017","journal-title":"Pediatr Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/s-0037-1618591","article-title":"A 5-Year follow-up of triple-seronegative myasthenia gravis successfully treated with tacrolimus therapy","volume":"49","author":"Tozawa","year":"2018","journal-title":"Neuropediatrics."},{"key":"B52","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.braindev.2012.06.012","article-title":"Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus","volume":"35","author":"Mori","year":"2013","journal-title":"Brain Dev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1586\/1744666X.2013.811042","article-title":"Breastfeeding and tacrolimus: is it a reasonable approach?","volume":"9","author":"Armenti","year":"2013","journal-title":"Expert Rev Clin Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.braindev.2006.02.001","article-title":"Successful treatment of a 2-year-old girl with intractable myasthenia gravis using tacrolimus","volume":"28","author":"Kakisaka","year":"2006","journal-title":"Brain Dev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/2576117X.2019.1578164","article-title":"Longstanding and refractory anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (Anti-MuSK-MG) in a child successfully treated with rituximab","volume":"69","author":"Weger","year":"2019","journal-title":"J Binocul Vis Ocul Motil."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.18295\/squmj.2018.18.02.018","article-title":"Rituximab treatment in myasthaenia gravis: report of two paediatric cases","volume":"18","author":"Koul","year":"2018","journal-title":"Sultan Qaboos Univ Med J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr."},{"key":"B59","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.nmd.2015.03.014","article-title":"Selective response to rituximab in a young child with MuSK-associated myasthenia gravis","volume":"25","author":"Govindarajan","year":"2015","journal-title":"Neuromuscul Disord."},{"key":"B60","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0303-8467(90)90057-C","article-title":"Results of an open trial of cyclosporine in a group of steroido-dependent myasthenic subjects","volume":"92","author":"Antonini","year":"1990","journal-title":"Clin Neurol Neurosurg."},{"key":"B62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology."},{"key":"B64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/mus.24536","article-title":"Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis","volume":"52","author":"Buzzard","year":"2015","journal-title":"Muscle Nerve."},{"key":"B66","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-019-09622-4","article-title":"Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis","volume":"267","author":"Gomez-Figueroa","year":"2020","journal-title":"J Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1212\/WNL.51.6_Suppl_5.S2","article-title":"Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0887-8994(99)00112-5","article-title":"High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis","volume":"22","author":"Selcen","year":"2000","journal-title":"Pediatr Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0887-8994(97)00136-7","article-title":"Juvenile myasthenia gravis: treatment with immune globulin and thymectomy","volume":"18","author":"Herrmann","year":"1998","journal-title":"Pediatr Neurol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology."},{"key":"B72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve."},{"key":"B73","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/cen3.12319","article-title":"Role of the thymus in autoimmune myasthenia gravis","volume":"7","author":"Berrih-Aknin","year":"2016","journal-title":"Clin Exp Neuroimmunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/CND.0b013e318253a48e","article-title":"Juvenile myasthenia gravis: a twenty-year experience","volume":"14","author":"Castro","year":"2013","journal-title":"J Clin Neuromuscul Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12883-019-1397-0","article-title":"Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study","volume":"19","author":"Chou","year":"2019","journal-title":"BMC Neurol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00383-017-4086-3","article-title":"The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review","volume":"33","author":"Madenci","year":"2017","journal-title":"Pediatr Surg Int."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1212\/WNL.44.7.1208","article-title":"Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis","volume":"44","author":"Andrews","year":"1994","journal-title":"Neurology."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.02.028","article-title":"Neonatal thymectomy in children-accelerating the immunological clock?","author":"Deya-Martinez","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/rheumatology\/key236","article-title":"Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study","volume":"58","author":"Chang","year":"2019","journal-title":"Rheumatology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00383-019-04486-1","article-title":"Pediatric thymectomy: a study of national trends in demographics, short-term outcomes, and cost","volume":"35","author":"Catalano","year":"2019","journal-title":"Pediatr Surg Int."},{"key":"B83","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00383-019-04441-0","article-title":"Thoracoscopic thymectomy for juvenile myasthenia gravis","volume":"35","author":"Kim","year":"2019","journal-title":"Pediatr Surg Int."},{"key":"B84","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/nyas.13538","article-title":"Therapeutic strategies for congenital myasthenic syndromes","volume":"1412","author":"Lee","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1060028019864574","article-title":"Amifampridine for the management of lambert-eaton myasthenic syndrome: a new take on an old drug","volume":"54","author":"Yoon","year":"2020","journal-title":"Ann Pharmacother."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2050312118819013","DOI":"10.1177\/2050312118819013","article-title":"Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study","volume":"6","author":"Bonanno","year":"2018","journal-title":"SAGE Open Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1460-9592.2005.01617.x","article-title":"Noninvasive ventilation options in pediatric myasthenia gravis","volume":"15","author":"Piastra","year":"2005","journal-title":"Paediatr Anaesth."},{"key":"B89","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British neurologists' management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol."},{"key":"B90","first-page":"905","article-title":"Safety of tacrolimus in pregnancy","volume":"60","author":"Nevers","year":"2014","journal-title":"Can Fam Physician."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00743\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T09:14:22Z","timestamp":1595582062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00743\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":90,"alternative-id":["10.3389\/fneur.2020.00743"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00743","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"article-number":"743"}}